The specialist pharmaceutical development company, Amzell BV has appointed Dr Alan Harris, as Chairman and former Chief Scientific Officer, Dr Dario Carrara as CEO. Amzell BV specialises in developing well-characterized active substances, utilizing innovative drug delivery technology platforms and has a number of drug candidates in its late stage development pipeline.

Dr Alan Harris, who will continue in his role as Senior VP in the Ferring Group’s R&D Management, has worked with the Ferring Group for more than 37 years, including leading the four BRIC R&D labs in Brazil, Russia, India, and China as part of Ferring’s pipeline expansion in these territories. Alan, who is located in Lausanne, Switzerland is a Board member of the Karolinska Institute spin-off company, Glucox Biopharma AB and a director of the Swiss based NGO, The ADEPT Foundation. Alan has a PhD in Biopharmaceutics from the Uppsala University, Sweden and an MBA from Ashridge Business School, UK.

Dr Dario Carrara was General Manager at Ferring, Allschwil as well as Chief Scientific Officer of Amzell before taking over as CEO. He was also the co-founder and Head of R&D at Permatec Pharma and Managing Director of Antares Pharma AG. Dario has a dual master’s degree in Pharmacy and Biochemistry, and received his PhD in Pharmaceutical Technology from the University of Buenos Aires. He is the inventor of more than 30 patents related to pharmaceutical composition and drug delivery technology.

Amzell CEO, Dario Carrara, comments, “We are delighted to have Alan join Amzell as Chairman. His extensive experience across research and development will be a huge asset for us, especially as we see a number of our product candidates approaching Phase 3 trials.”

Amzell is a specialist pharmaceutical development company focused on developing well-characterized active substances through to proof-of-concept or marketing authorization for sale to commercial partners. Amzell’s innovative platforms and drug delivery technologies provide effective drug delivery, increased efficacy, and improved safety and compliance. The latest product in its portfolio to reach Phase 3 is AMZ002, an innovative new treatment for infantile epileptic disease.